close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

45.00 +0.56 (+1.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Recap: Supernus Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Supernus Pharmaceuticals: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease ↗
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Supernus Provides Regulatory Update for SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotechnology And Healthcare, A Bit Of A Lull ↗
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors. 
Via Talk Markets
News headline image
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential ↗
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. 
Via InvestorPlace
News headline image
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings ↗
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
News headline image
Supernus Announces Third Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 8, 2023 ↗
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Supernus to Participate in the Jefferies London Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
PDUFA Target Action Date of April 5, 2024 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today